New Risk • Aug 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł9.4m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Revenue is less than US$1m (zł30k revenue, or US$8.1k). Minor Risk Market cap is less than US$100m (zł61.5m market cap, or US$16.5m). New Risk • Jan 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 1.1% per year over the past 5 years. Revenue is less than US$1m (zł15k revenue, or US$4.2k). Minor Risk Market cap is less than US$100m (zł86.8m market cap, or US$24.5m). New Risk • Nov 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.2% per year over the past 5 years. Revenue is less than US$1m (zł11k revenue, or US$3.0k). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (zł69.2m market cap, or US$18.8m). Reported Earnings • Oct 05
Second quarter 2025 earnings released: zł0.22 loss per share (vs zł0.23 loss in 2Q 2024) Second quarter 2025 results: zł0.22 loss per share (improved from zł0.23 loss in 2Q 2024). Net loss: zł3.35m (flat on 2Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 11% per year. お知らせ • Aug 25
Genomtec S.A. to Report First Half, 2025 Results on Sep 29, 2025 Genomtec S.A. announced that they will report first half, 2025 results on Sep 29, 2025 New Risk • May 18
New major risk - Revenue and earnings growth Earnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł9.7m free cash flow). Earnings have declined by 0.2% per year over the past 5 years. Revenue is less than US$1m (zł1.0k revenue, or US$261). Minor Risk Market cap is less than US$100m (zł98.1m market cap, or US$25.6m). お知らせ • May 12
Genomtec S.A., Annual General Meeting, Jun 05, 2025 Genomtec S.A., Annual General Meeting, Jun 05, 2025. Reported Earnings • Dec 01
Third quarter 2024 earnings released: zł0.25 loss per share (vs zł0.23 loss in 3Q 2023) Third quarter 2024 results: zł0.25 loss per share (further deteriorated from zł0.23 loss in 3Q 2023). Net loss: zł3.29m (loss widened 21% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 02
Second quarter 2024 earnings released: zł0.23 loss per share (vs zł0.15 loss in 2Q 2023) Second quarter 2024 results: zł0.23 loss per share (further deteriorated from zł0.15 loss in 2Q 2023). Net loss: zł3.38m (loss widened 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. New Risk • Sep 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.0m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Shareholders have been diluted in the past year (8.7% increase in shares outstanding). Market cap is less than US$100m (zł106.6m market cap, or US$27.9m). お知らせ • May 31
Genomtec S.A., Annual General Meeting, Jun 25, 2024 Genomtec S.A., Annual General Meeting, Jun 25, 2024. New Risk • Apr 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 56% over the past year. Revenue is less than US$1m (zł19k revenue, or US$4.7k). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (zł156.7m market cap, or US$38.7m). New Risk • Nov 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 59% over the past year. Revenue is less than US$1m (zł18k revenue, or US$4.5k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł132.4m market cap, or US$33.3m). New Risk • Nov 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Revenue has declined by 63% over the past year. Revenue is less than US$1m (zł24k revenue, or US$5.8k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-zł10m). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł140.4m market cap, or US$33.8m). Reported Earnings • Jun 02
First quarter 2023 earnings released: zł0.20 loss per share (vs zł0.088 loss in 1Q 2022) First quarter 2023 results: zł0.20 loss per share (further deteriorated from zł0.088 loss in 1Q 2022). Net loss: zł2.08m (loss widened 191% from 1Q 2022). お知らせ • Jun 02
Genomtec S.A., Annual General Meeting, Jun 27, 2023 Genomtec S.A., Annual General Meeting, Jun 27, 2023, at 13:30 Central European Standard Time.